Diaverum expands in Brazil with vascular access centre acquisition
Diaverum, a leading global renal care service provider, takes a further step towards establishing an integrated dialysis care offering in Brazil, through the acquisition of the vascular access centre, ACS Brasil Cirurgica Ltda.
ACS Brasil Cirurgica Ltda is a high-quality vascular access (VA) centre located in São Paulo, one of the largest cities in Latin America. Founded in 2010, it performs more than 4,500 procedures per year, including procedures related to Arteriovenous Fistula (AVF), prosthesis and catheter for both peritoneal and haemodialysis treatments, among others. Morbidity related to vascular access is a major cause of hospitalisation for chronic haemodialysis patients and is associated with high cost of care.
Luciano Bonaldo, Diaverum Brazil Country Manager, said: "This acquisition is aligned with our strategy to consolidate an integrated dialysis care programme in Brazil, where we take broader responsibility on patient healthcare needs beyond dialysis to improve medical outcomes and reduce the total cost of care for the payor. This acquisition will help strengthen the Diaverum brand in the Brazilian healthcare sector, as the renal care provider of choice for renal patients and the country’s healthcare system”.
Dr Gelba Almeida, Diaverum Brazil Medical Director, added: “We are very pleased to welcome the ACS team into the Diaverum family. Delivering vascular access management in-house has many direct and indirect benefits, such as being responsible for the quality control of VA-related procedures to improve patient outcomes. With this acquisition, we intend to reduce infections and hospitalisations, consequently reducing patient absence and in turn, enabling them to live fulfilling lives”.
VA management is central to Diaverum’s clinical strategy
Alongside promoting and establishing integrated dialysis care services that include VA management across its markets, the company has developed a breakthrough AI model to deliver a step-change in VA thrombosis prevention.
Announced on 14 October, Diaverum’s innovative AI model supports the company’s physicians and nurses predict episodes of VA thrombosis among haemodialysed patients one week before they occur. Simulations using Diaverum’s patient data predicted an average of 75% of actual cases that were not detected by best-in-class clinical assessments and monitoring systems.
Starting with its operations in Saudi Arabia, Portugal and Spain, the company’s objective is to roll out the model to its entire network of 452 clinics in 24 countries – including Brazil – over the next 18 months.
Diaverum provides life enhancing renal care to patients with Chronic Kidney Disease (CKD), enabling them to live fulfilling lives. Diaverum is a leading global provider in renal care services, and we help some 40,000 patients with 6.2 million treatments annually. Our vision is to transform renal care, to deliver the highest quality of care for patients and reduce total cost of care for payers. Our focus is haemodialysis, but we offer a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to coordination of patients’ comorbidities, transplantation services and holiday dialysis. Diaverum employs around 14,000 people and operates 452 clinics in 24 countries globally. Diaverum has its head office in Malmö, Sweden.